Quantum BioPharma Ltd. (QNTM) - Total Assets
Based on the latest financial reports, Quantum BioPharma Ltd. (QNTM) holds total assets worth $14.15 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore QNTM operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
Quantum BioPharma Ltd. - Total Assets Trend (2015–2024)
This chart illustrates how Quantum BioPharma Ltd.'s total assets have evolved over time, based on quarterly financial data. See QNTM net asset value for net asset value and shareholders' equity analysis.
Quantum BioPharma Ltd. - Asset Composition Analysis
Current Asset Composition (December 2024)
Quantum BioPharma Ltd.'s total assets of $14.15 Million consist of 70.4% current assets and 29.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 35.0% |
| Accounts Receivable | $3.81 Million | 22.2% |
| Inventory | $117.24K | 0.7% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $4.93 Million | 28.8% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2015–2024)
This chart illustrates how Quantum BioPharma Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Quantum BioPharma Ltd. market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Quantum BioPharma Ltd.'s current assets represent 70.4% of total assets in 2024, a decrease from 100.0% in 2015.
- Cash Position: Cash and equivalents constituted 35.0% of total assets in 2024, up from 0.0% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 28.0% of total assets, an increase from 0.0% in 2015.
- Asset Diversification: The largest asset category is intangible assets at 28.8% of total assets.
Quantum BioPharma Ltd. Competitors by Total Assets
Key competitors of Quantum BioPharma Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
Quantum BioPharma Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.41 | 3.76 | 4.82 |
| Quick Ratio | 1.39 | 3.76 | 4.82 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $2.70 Million | $10.16 Million | $21.29 Million |
Quantum BioPharma Ltd. - Advanced Valuation Insights
This section examines the relationship between Quantum BioPharma Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.63 |
| Latest Market Cap to Assets Ratio | 0.65 |
| Asset Growth Rate (YoY) | -2.0% |
| Total Assets | $17.12 Million |
| Market Capitalization | $11.11 Million USD |
Valuation Analysis
Below Book Valuation: The market values Quantum BioPharma Ltd.'s assets below their book value (0.65x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Quantum BioPharma Ltd.'s assets decreased by 2.0% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Quantum BioPharma Ltd. (2015–2024)
The table below shows the annual total assets of Quantum BioPharma Ltd. from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $17.12 Million | -2.03% |
| 2023-12-31 | $17.47 Million | -54.51% |
| 2022-12-31 | $38.41 Million | -38.99% |
| 2021-12-31 | $62.96 Million | +50.03% |
| 2020-12-31 | $41.97 Million | -2.89% |
| 2019-12-31 | $43.22 Million | +11.53% |
| 2018-12-31 | $38.75 Million | +256.19% |
| 2017-12-31 | $10.88 Million | +152320.99% |
| 2016-12-31 | $7.14K | +230.34% |
| 2015-12-31 | $2.16K | -- |
About Quantum BioPharma Ltd.
Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. It operates through two segments, Biopharmaceutical Innovation and Strategic Investments. The company researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in d… Read more